Genetic elevation of monoamine oxidase levels in dopaminergic PC 12 cells results in increased free radical damage and sensitivity to MPTP

Journal of Neuroscience Research

Volumn 46, Issue 6, 1996, Pages 666-673

  Wei, Q ^b   Yeung, M ^a   Jurma, O P ^a,b   Andersen, J K ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Deprenyl; Free radicals; Monoamine oxidase B; MPTP susceptibility; PC12; Vitamin E

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMINE OXIDASE (FLAVIN CONTAINING); DOPAMINE; FREE RADICAL; HYDROGEN PEROXIDE; PHENETHYLAMINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CATECHOLAMINE SYNTHESIS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; ENZYME REGULATION; GENETIC SUSCEPTIBILITY; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REACTION ANALYSIS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CELL SURVIVAL; DOPAMINE; DOPAMINE AGENTS; FREE RADICALS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; MONOAMINE OXIDASE; MONOAMINE OXIDASE INHIBITORS; NEUROTOXINS; PC12 CELLS; PLASMIDS; RATS; SELEGILINE; SENSITIVITY AND SPECIFICITY; VITAMIN E;

EID: 0030479501     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19961215)46:6<666::AID-JNR3>3.0.CO;2-D     Document Type: Article

References (48)

1. Andersen JK, Prim DM, Isacson O, Breakefield XO (1994a): Catecholaminergic cell atrophy in a transgenic mouse aberrently overexpressing MAO-B in neurons. Neurodegeneration 3:97-109.
2. Andersen JK, Frim DM, Isacson O, Beal MF, Breakefield XO (1994b): Elevation of MAO-B in a transgenic mouse model has no effect on MPTP sensitivity. Brain Res 656:108-114.
3. Behl C, Davis JB, Lesley R, Schubert D (1994): Hydrogen peroxide mediates amyloid β protein toxicity. Cell 77:817-827.
4. Ben-Shacher D, Eschel G, Riederer P, Youdim MB (1992): Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implications for Parkinson's disease. Ann Neurol 32: S105-S110.
5. Buckman TD, Sutphin MS, Mitrovic B (1993): Oxidative stress in a clonal cell line of neuronal origin: Effects of antioxidant enzyme modulation. J Neurochem 60:2046-2058.
6. Cohen G (1986): Monoamine oxidase, hydrogen peroxide, and Parkinson's disease. Adv Neurol 45:119-125.
7. Denton T, Howard BD (1987): A dopaminergic cell line variant resistant to the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49:622-630.
8. Dexter DT, Wells F, Lees J, Agid F, Agid Y, Jenner P, Marsden CD (1989a): Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836.
9. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989b): Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 52:381-389.
10. Feiten DL, Feiten SY, Steece-Collier K, Date I, Clemens JA (1992): Age-related decline in the dopaminergic nigrostriatal system: the oxidative hypothesis and protective strategies. Ann Neurol 32:8133-6.
11. Fowler CJ, Wiberg A, Oreland L, Marcusson J, Wineblad B (1980): The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm 49:1-20.
12. Graham DG (1984): Catecholamine toxicity: A proposal for the molecular pathogenesis of manganese neurotoxicity and Parkinson's disease. Neurotoxicol 5:83-95.
13. Greene LA and Tischler AS (1976): Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci USA 73: 2424-2428.
14. Gupta M, Gupta BK, Thomas R, Bruemmer V, Sladek JR Jr, Felten DL (1986): Aged mice are more sensitive to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment than young adults. Neurosci Lett 70:326-31.
15. Halliwell B, Gutteridge JMC (1985): Oxygen radicals and the nervous system. Trends Neurosci 8:22-26.
16. Halliwell B (1992): Reactive oxygen species and the central nervous system. J Neureichem 59:1609-1623.
17. Hansen MB, Nielson SE, Berg K (1989): Re-examination and further development of precise and rapid dye method for measuring cell growth/cell killing. J Immunol Meth 119:203-210.
18. Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984): Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridone by monoamine oxidase inhibitors. Nature 311:467-469.
19. Hirsch EC (1992): Why are catecholaminergic neurons more vulner-able than other cells in Parkinson's disease? Ann Neurol 32: S88-S93.
20. Javitch JA, D'amato RJ, Strittmatter SM, Snyder S (1985): Parkinsonism-inducing neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
21. Kinemuchi H, Wakui Y, Toyoshima Y, Hayashi N, Kamijo K (1979): A concentration dependent preferential substrate for the multiple forms of MAO. In Singer TP, Von Korff RW, Murphy DL (eds): Monoamine Oxidase: Structure, Function, and Altered Functions. New York: Academic Press, pp 205-212.
22. Korcherberger LM, Parker EL, Siciliano M, Darlington JG, Denney RM (1986): Assignment of genes for human oxidases A and B to the X chromosome. J Neurosci Res 16:601-616.
23. Koh JY, Choi DW (1987): Quantitative determination of glutamate mediated corticol neuronal injury in cell culture by lactate dehydrogenase efflux assay. J Neurochem Methods 20:83-90.
24. Levine RL, Garland D, Oliver CN, Amici A, Climent I, Lenz AG, Ahn BW, Shaltiel S, Stadtman ER (1990): Determination of carbonyl content in oxidatively modified proteins. Meth Enzymol 186:464-478.
25. Levitt P, Pintar JE, Breakefield XO (1982): Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotoninergic neurons. Proc Natl Acad Sci USA 79:6385-6389.
26. Makar TK, Nedergaard M, Preuss A, Gelbard AS, Perumal AS, Cooper, AJL (1994): Vitamin E, ascorbate, glutathione, glutathione disulfide, and enzymes of glutathione metabolism in cultures of chick astrocytes and neurones: evidence that astrocytes play an important role in anti-oxidative processes in the brain. J Neurochem 62:45-53.
27. Maue RA, Kraner SD, Goodman RH, Mandel G (1990): Neuronspecific expression of the rat brain type II sodium channel gene is directed by upstream regulatory elements. Neuron 4:223-231.
28. Mo J-Q, Hom DG, Andersen, JK (1995) Oxidative damage in aged mouse brain correlates with decreases in protective enzymes. Mech Aging Dev 81:73-82.
29. Murphy DL, Wright C, Buchsbaum M, Nichols A, Costa JL, Wyatt RJ (1976): Platelet and plasma amine oxidase activity in 680 normals: Sex and age differences and stability over time. Biochem Med 16:254-265.
30. O'Carroll AM, Andeson MC, Tobbia I, Phillips JP, Tipton KF (1989): Determination of absolute concentrations of monoamine oxidase A and B in various human tissues. Biochem Pharmacol 38:901-905.
31. Olanow CW (1992): An introduction to the free-radical hypothesis in Parkinson's disease. Ann Neurol 32:S2-S9.
32. Olanow CW (1993): A radical hypothesis for neurodegeneration. Trends Neurosci 16:439-444.
33. Raps SP, Lai JCK, Hertz L, Cooper AJL (1989): Glutathione is present in high concentration in cultured astrocytes but not in cultured neurons. Brain Res 493:398-401.
34. Riley LA, Denney RM (1991): Problems with the measurement of monoamine oxidase A protein concentration in mitochondrial preparations. Biochem Pharmacol 42:1953-1959.
35. Sagara J, Miura K, Bannai S (1993): Maintenance of neuronal glutathione by glial cells. J Neurochem 61:1672-1676.
36. Sanchez-Ramos JR, Overvik E, Ames BN (1994): A marker of oxyradical-mediated DNA damage (8-Hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204.
37. Saura J, Richards JG, Many N (1993): Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol Aging 15:399-408.
38. Singer TP, Castanoli N Jr, Ramsey RR, Trevor AJ (1987): Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurochem 49:1-8.
39. Sofie E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991): Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56:978-982.
40. Stadtman ER (1992): Protein oxidation and aging. Science 257:1220-1224.
41. Troy CM and Shelanski ML (1994): Down-regulation of copper/zinc superoxide dismutase causes apoptotic death in PC12 neuronal cells. Proc Natl Acad Sci USA 91:6384-6387.
42. Weyler W, Hsu YP, Breakefield XO (1990): Biochemistry and genetics of monoamine oxidase. Pharmacol Ther 47:391-417.
43. Westlund KN, Denney RM, Kochersperger LM, Rose RM, Abell CW (1985): Distinct monoamine oxidase A and B populations in primate brain. Science 230:181-183.
44. Westlund KN, Denney RM, Rose RM, Abell CW (1988): Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25:439-456.
45. Whittemore ER, Loo DT, Cotman CW (1994): Exposure to hydrogen peroxide induces cell death via apoptosis in cultured rat cortical neurons. NeuroReport 5:1485-1488.
46. Wilber KM, Bernheim F, Shapiro OW (1949): The thiobarbituric acid test for the oxidation of unsaturated fatty acids by various agents. Arch Biochem Biophys 24:305-313.
47. Youdim MB (1991): PC12 cells as a window for the differentiation of neural crest into adrenergic nerve ending and adrenal medulla. J Neural Transm Suppl 34:61-67.
48. Zaleska MM, Nagy K, Floyd RA (1985). Regional lipid peroxidation in rat brain in vitro: Possible role of endogenous iron. Neurochem Res 10:397-410.